Aligos Therapeutics, Inc. (NASDAQ:ALGS - Get Free Report)'s stock price traded up 1.8% during mid-day trading on Wednesday . The company traded as high as $9.44 and last traded at $9.28. 46,007 shares traded hands during trading, a decline of 79% from the average session volume of 215,144 shares. The stock had previously closed at $9.12.
Analyst Ratings Changes
Separately, HC Wainwright reissued a "buy" rating and set a $70.00 target price on shares of Aligos Therapeutics in a research note on Monday, March 31st.
Get Our Latest Report on Aligos Therapeutics
Aligos Therapeutics Stock Performance
The stock has a market cap of $55.78 million, a price-to-earnings ratio of -0.52 and a beta of 2.77. The stock's 50-day simple moving average is $7.43 and its two-hundred day simple moving average is $12.25.
Aligos Therapeutics (NASDAQ:ALGS - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported ($2.11) earnings per share for the quarter, topping analysts' consensus estimates of ($2.80) by $0.69. The firm had revenue of $0.31 million during the quarter, compared to analyst estimates of $0.33 million. Aligos Therapeutics had a negative net margin of 1,628.75% and a positive return on equity of 14.67%. As a group, research analysts predict that Aligos Therapeutics, Inc. will post -10.36 earnings per share for the current year.
Hedge Funds Weigh In On Aligos Therapeutics
Hedge funds and other institutional investors have recently bought and sold shares of the business. Adage Capital Partners GP L.L.C. raised its holdings in shares of Aligos Therapeutics by 43.1% during the first quarter. Adage Capital Partners GP L.L.C. now owns 465,000 shares of the company's stock worth $3,836,000 after acquiring an additional 140,000 shares during the period. Alyeska Investment Group L.P. purchased a new position in Aligos Therapeutics in the 1st quarter worth about $3,399,000. Woodline Partners LP purchased a new position in Aligos Therapeutics in the 1st quarter worth about $2,602,000. Heights Capital Management Inc. purchased a new position in Aligos Therapeutics in the 1st quarter worth about $1,992,000. Finally, Trexquant Investment LP purchased a new position in Aligos Therapeutics in the 4th quarter worth about $2,751,000. 60.43% of the stock is owned by institutional investors.
About Aligos Therapeutics
(
Get Free Report)
Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).
Read More
Before you consider Aligos Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aligos Therapeutics wasn't on the list.
While Aligos Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
